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Abstract: “Small-for-size” livers arising in the context of liver resection and transplantation
are vulnerable to the effects of increased portal flow in the immediate postoperative period.
Increased portal flow is an essential stimulus for liver regeneration. If the rise in flow and stimulus
for regeneration are excessive, however, liver failure and patient death may result. Somatostatin is an
endogenous peptide hormone that may be administered exogenously to not only reduce portal blood
flow but also offer direct protection to different cells in the liver. In this review article, we describe
key changes that transpire in the liver following a relative size reduction occurring in the context
of resection and transplantation and the largely beneficial effects that peri-operative somatostatin
therapy may help achieve in this setting.
Keywords: liver regeneration; liver resection; liver transplantation; portal hypertension;
post-hepatectomy liver failure; “small-for-size” syndrome
1. Introduction
The liver is an important organ that fulfills vital functions of metabolism, synthesis, storage, and
redistribution of carbohydrates, fats, vitamins, and other nutrients [1]. When partially removed or
damaged, the liver also has incredible potential for regrowth. It is this last fact that has allowed for
the development of modern surgical practices in which a significant portion of the liver is resected or,
in some cases, transplanted, largely without major clinical repercussion. There is a limit as to how
much liver may be safely left in a particular patient, however, and this limit currently represents the
greatest challenge facing both hepatobiliary and transplant surgeons in their attempts to radically
remove primary and metastatic liver tumors, as well as to transplant partial liver grafts to treat patients
with end-stage liver disease.
In the settings of major liver resection and liver transplantation, in particular using reduced-size
livers, there is an acute increase in portal vein flow (PVF) to a mass of liver accustomed to lower
flow-per-unit of tissue. This increase in PVF serves as a stimulus for a subsequent series of intrahepatic
events that are necessary to achieve liver regeneration and repair. At the same time, if the increase and
stimulus are excessive, liver insufficiency and even failure may develop.
“Small-for-size” syndrome (SFSS) (also known as post-hepatectomy liver failure, PHLF, in the
context of liver resection) is one of the most feared consequences of partial liver transplantation
and major hepatectomy. Characterized by progressive cholestasis, coagulopathy, encephalopathy,
ascites, gastrointestinal bleeding and/or renal failure, the development of post-operative SFSS/PHLF is
associated with high morbidity and short-term mortality rates of up to 80%. For this reason, careful
surgical planning is critical to ensure “safe” graft or remnant liver >25–30% of its pre-operative mass
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or volume in patients with normal livers or >40% in livers that are cirrhotic, cholestatic, steatotic,
or injured by chemotherapy [2–5].
Somatostatin is a naturally occurring peptide hormone that exerts a number of effects in living
organisms, the majority of which are inhibitory. Due to its specific actions in the splanchnic vasculature,
it has found a special role in helping to avoid the adverse effects of hyperdynamic splanchnic and
portal blood flow in different clinical situations. In the present review article, we discuss the current
understanding of key changes occurring in the immediate period following major liver resection
and partial liver transplantation and the effects and outcomes that have been achieved following
peri-operative administration of somatostatin in these settings.
2. Changes Occurring in the “Small-For-Size” Liver
Liver regeneration is a complex and not entirely understood process. In-depth discussion of liver
regeneration is beyond the scope of the present manuscript, and we refer the readership to recent and
more comprehensive reviews on the topic [6,7]. Briefly, upon reduction of functional liver mass, PVF to
the remnant liver increases, exerting a mechanical effect in the hepatic sinusoids. Rapid remodeling
of the extracellular matrix (ECM) leads to release and activation of hepatocyte growth factor (HGF),
previously produced by hepatic stellate cells (HSCs) and embedded in its precursor form in the
ECM [8]. Interaction between HGF and its tyrosine kinase receptor, Met, as well as activation of
epidermal growth factor (EGF) receptor occurs very early after partial hepatectomy, indicating the
action of preformed ligands (HGF from the ECM, EGF from the portal vein) [6]. Post-hepatectomy
increase in PVF also brings a higher volume of metabolites and signaling molecules to the hepatocytes.
Elevation in circulating levels of the cytokines tumor necrosis factor-α and interleukin-6 primes
hepatocytes to respond to the mitogenic signals of growth factors, including HGF and EGF, as well as
transforming growth factor-α, heparin-binding EGF-like growth factor, and amphiregulin, to enter the
cell cycle [9–11].
In addition to cytokines and mitogenic growth hormones, levels of bile acids also increase rapidly
in the liver after partial hepatectomy, and bile acids are necessary for normal liver regeneration
to occur. Bile acids bind the farnesoid X receptor (FXR), which not only triggers pro-mitogenic
mechanisms but also protects the liver parenchyma against the accumulation of toxic hydrophobic bile
acids. Farnesoid X receptor binds both conjugated and unconjugated bile acids and is expressed in
hepatocytes as well as the terminal ileum. In hepatocytes, FXR controls the expression of genes involved
in the synthesis (e.g., cholesterol 7α-hydroxylase, CYP7A1), conjugation, uptake, and secretion of
bile acids [12]. In enterocytes, binding triggers activation of genes involved in bile acid transport and
transcription of fibroblast growth factor (FGF) 15 in mice/FGF19 in humans. FGF15/19 reaches the liver
through portal circulation and binds the complex of FGFR4 and its co-receptor β-Klotho to suppress
the expression of CYP7A1, thereby suppressing further bile acid synthesis [7,13].
In human whole liver transplantation, blood flow to the graft increases upon reperfusion in
the recipient [14]. Flows can more than double due to the loss of normal vascular tone and the
persistence of abnormal splanchnic hemodynamics. Normal liver tissue is capable of supporting up to
between two- and three-times its standard PVF, and this increase is an important stimulus for hepatic
regeneration [15–17]. Portal vein flow in excess of this threshold, however, can be detrimental to
liver function and survival and significantly increases the risk for the development of SFSS/PHLF
in the post-operative period [17–22]. This is due not only to mechanical shear stress-induced injury
to the cells lining the hepatic sinusoids, including sinusoidal endothelial cell (SEC) denudation and
dissection of blood into the peri-portal spaces and beyond [21], but also disproportionate restoration of
parenchymal and non-parenchymal cells in the regenerating liver.
At the clinical level, little information has been published regarding the histological changes
associated with the development of SFSS. Demetris et al. described five cases of SFSS in adult-to-adult
living-donor liver transplantation, including three with needle biopsies coinciding with the onset
of clinical signs suggestive of SFSS (e.g., cholestasis). In these biopsies, in addition to centrilobular
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cholestasis, there was some evidence of SEC injury as well as hepatocellular swelling and acute cellular
rejection in all cases [23]. Gruttadauria and colleagues also looked at human livers developing SFSS after
both partial liver transplantation and extended hepatectomy and observed centrilobular cholestasis,
focal endothelial denudation in the portal vein, and immunohistochemical overexpression of Ki-67 [24].
This last finding—overexpression of the cellular proliferation marker Ki-67—is particularly interesting
and points to a pattern of excessive regrowth of hepatocytes that predominates at the time of and may
ultimately be the cause of liver failure. This theory of excessive hepatocellular regeneration helps
to explain the delay typically seen between surgery and clinical signs and symptoms of SFSS (as its
presentation in humans is generally subacute) and to provide a unifying pathophysiological basis for
“small-for-size” liver failure after both transplantation, where PVF may be hyperdynamic at baseline,
and major hepatectomy, where PVF is largely—at least initially—normal.
To understand how hepatocellular regeneration might be “excessive” and how this could
be detrimental requires knowledge of how parenchymal and non-parenchymal cells are replaced.
Following major size reduction, original liver mass is re-established in a period of weeks in humans,
but this does not occur as a balanced process at the cellular level. Timing of regeneration varies
according to not only spatial localization but also cell type. Cellular proliferation starts in peri-portal
cells (zone 1) and then progresses through midzonal cells (zone 2), and finally reaches the cells closest to
the central vein (zone 3). Additionally, during hepatic regeneration, entry into the cell cycle and DNA
synthesis occur earlier in hepatocytes versus non-parenchymal cells. For example, DNA synthesis
in hepatocytes begins to increase after approximately 12 h and peaks at 24 h in rats (around 36 h
in mice), whereas it begins around 48 h in cholangiocytes and Kupffer cells and 96 h in SECs [9,25].
This order of events results in the formation of avascular clusters of 10 to 14 hepatocytes devoid of
extracellular matrix, the so-called “hepatocyte islands”, which persist until SECs are replicated and the
normal extracellular matrix is restored [26] (Figure 1). Consequently, reformation of the normal liver
microarchitecture occurs sometime after the original mass has been replaced.
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Hepatocyte islands, which are formed mainly in zones 1 and 2, are considered less functional
than normal single-cell-wide hepatocyte plates due to the fact that there are fewer sinusoids and bile
canaliculi for each hepatocyte. It therefore follows that the smaller the remnant liver, the greater is the
proportion of hepatocytes entering the replicative process to form these islands, decreasing the amount
of functional liver tissue available even as gross mass is restored [27]. For this reason, several studies
have reported that functional regeneration does not correlate with volumetric regeneration during the
early stages of liver regrowth [21,28–31], and that strategies that decelerate regeneration can actually
lead to better preservation of normal hepatic microarchitecture and improved survival during the
regeneration process [17,22,32].
3. Somatostatin Mechanisms of Action
Somatostatin produces a range of actions via binding to the five somatostatin receptor (SSTR)
subtypes. Each SSTR associates with heterotrimeric guanine nucleotide-binding proteins (G-proteins)
to mediate the inhibition of adenylyl cyclase activity, primarily, as well as mitogen-activated protein
kinase and various phosphatases and ion channels [33,34]. Injury, cytokines, growth factors (including
insulin and growth hormone, GH), and somatostatin itself regulate SSTR gene expression [35–38].
Initial responses of SSTR binding are diminished by continuous exposure via mechanisms of receptor
desensitization, internalization, and degradation [35,39].
Given that the half-life of somatostatin is very short (1–2 min), it has to be administered as a
continuous infusion when applied in vivo. Somatostatin analogues such as octreotide, lanreotide,
vapreotide, and pasireotide are more resistant to endogenous peptidases and have significantly
longer half-lives than native somatostatin (approximately 2 h for octreotide and lanreotide, 3–4 h for
vapreotide, and 12 h for pasireotide) [40]. However, native somatostatin and its synthetic analogues
have different affinities for the five SSTR subtypes. Native somatostatin binds all five. Octreotide and
lanreotide bind to SSTR2 and SSTR5 and moderately to SSTR3. Vapreotide binds SSTRs 2, 3, and 5
and moderately to SSTR4. Pasireotide has high affinity for SSTRs 1, 2, 3, and 5, making it, in theory,
the analogue with the greatest capacity to reproduce the various effects of native somatostatin [41].
Octreotide is the only analogue, however, that has been specifically tested in “small-for-size” livers;
while it has never been compared with native somatostatin in this setting, similar effects have been
reported for both drugs (see the following section on “Somatostatin and the ‘Small-For-Size’ Liver
In Vivo”).
3.1. Splanchnic Vasculature
Somatostatin receptors, in particular SSTR2, are expressed on endothelial cells. By binding
to its receptors in the portomesenteric vasculature, somatostatin can help decrease portal venous
pressure (PVP) and splanchnic blood flow in a dose-dependent manner [42,43]. Somatostatin induces
vasoconstriction in the mesenteric arteries and portocollateral veins [44,45]. It also inhibits secretion
of gut-derived vasodilatory peptides, such as glucagon, vasoactive intestinal peptide, and substance
P [46–48]. For this reason, somatostatin has found clinical application in the treatment of acute
gastroesophageal hemorrhage in portal hypertensive patients.
3.2. Liver
In the normal innervated liver, somatostatin-containing axons are present in the spaces of Disse
and exert paracrine effects on nearby cells, depending on the expression of SSTR subtypes [49].
Receptor expression is limited to cholangiocytes and a small number of endothelial cells lining the
hepatic arterioles in the normal liver; after liver injury, however, be it acute or chronic, both hepatocytes
and HSCs may express all five SSTR subtypes [22,37,50–52].
Once it binds, the action of somatostatin on hepatocytes includes inhibition of hepatotropic
factor-mediated hepatocellular proliferation and DNA synthesis when administered prior to partial
hepatectomy [53–55]. Somatostatin reduces hepatocellular sensitivity to GH by internalizing GH
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receptors and by decreasing transcription of GH receptor mRNA. As well, it reduces basal and
GH-stimulated insulin-like growth factor 1 production in the liver and suppresses the secretion of
pro-inflammatory cytokines, many of which are also implicated in hepatic regeneration [34,56–58].
The combined effects of somatostatin in the pre-portal vasculature and the liver itself make somatostatin
an inhibitor of hepatocellular regeneration. At the same time, however, regenerating hepatocytes may
actually down-regulate the expression of somatostatin binding sites, thereby counteracting, at least in
part, the suppression of proliferation that somatostatin may exert [53,59]
In addition to hepatocytes, somatostatin may also enact effects on non-parenchymal cells in the
liver. While phenotypically injured SECs do not appear to respond to somatostatin directly [22],
injured SECs produce endothelin-1 (ET-1), a potent vasoconstrictive peptide that provokes contraction
of HSCs. By binding to HSCs (via SSTR1, in particular), somatostatin reduces ET-1-mediated HSC
contraction and helps restore the normal hepatic sinusoidal diameter [37].
3.3. Potential Side Effects
At standard clinical doses, somatostatin is a relatively safe drug, with few and mostly initial
side effects that include nausea, cramps, diarrhea, steatorrhea, and occasionally hyperglycemia [60].
Somatostatin and its analogues have been used for prolonged periods, especially in the treatment
of neuroendocrine tumors, and generally appear to be non-toxic [61], though chronic use of
second-generation analogues, such as pasireotide, may lead to the development of secondary diabetes.
Somatostatin is considered to be the safest therapy for the acute treatment of bleeding gastroesophageal
varices [62]. In some animal models, however, acute high-dose therapy has been seen to induce
ventilatory depression, blunted responses to hypoxic and hypercapnic stimuli, and even apnea [22,63].
Water intoxication and hyponatremia are also a rare but potentially devastating consequences of
somatostatin use [64]. For this reason, patients receiving peri-operative somatostatin infusion should
have serum sodium levels checked daily.
4. Somatostatin and the “Small-For-Size” Liver In Vivo
Somatostatin and its analogues exert numerous concrete effects in the portal and pre-portal
vasculature and liver itself. Results of in vivo studies that have been performed in animals and a few
in humans help determine whether, on the whole, the balance of these effects may be beneficial or
detrimental in “small-for-size” liver remnants and grafts.
4.1. Following Major Hepatectomy
Administration of the somatostatin analogue octreotide following 70% hepatectomy in rats has
been shown to reduce the restoration of hepatic mass measured up to two weeks post-operatively.
While hepatocellular proliferation is reduced, hepatocyte cords in regenerating livers treated with
octreotide maintain a more normal morphology compared with untreated controls. Peri-operative
octreotide therapy has also been shown to result in improved hepatic reticuloendothelial system
activity, with greater cholangiolar and Kupffer cell proliferation, and less growth of inoculated cancer
cells (colonic adenocarcinoma, fibrosarcoma) in regenerating livers [65,66]. Albeit not the objective of
its acute administration, somatostatin and its analogues are known to have tumor suppressive effects
in both primary and metastatic liver tumors [67–73], and tumor suppression could potentially be a
beneficial collateral effect of peri-operative somatostatin or analogue therapy.
In a more extreme model of 90% hepatectomy in rats, peri-operative octreotide therapy
significantly improved liver histology, function, and survival, while simultaneously inhibiting early
liver regeneration. This study also determined that octreotide altered the levels of metabolites that
participate in or are closely associate with the methionine (Met) cycle, a biochemical reaction that
produces S-adenosylmethionine (SAMe), an active methyl residual donor for methyltransferase
reactions. In particular, 5’-methylthioadenosine (5’-MTA), a metabolite produced when SAMe is
shunted out of the Met cycle to the Met salvage pathway, was significantly increased and was found
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through exogenous administration to improve hepatic histology and reduce inflammatory cytokines
following extended hepatectomy [74]. This preliminary finding is intriguing given the anti-oxidant,
anti-inflammatory, and even anti-fibrotic effects that have been ascribed to 5’-MTA [75–77].
Somatostatin therapy was shown in a non-survival model of 70% and 90% porcine hepatectomies
to significantly reduce post-resection PVF and hepatic venous pressure gradient (HVPG) [78]. In a
recent pilot study in humans, somatostatin therapy was initiated intraoperatively following completion
of major hepatectomy when the post-resection PVP was >20 mmHg. Somatostatin bolus (250 µg)
immediately reduced PVP in the majority of cases and was maintained as a continuous 250-µg/h
infusion given over the course of five days. Among ten patients treated in this fashion, three (30%)
developed PHLF; one case of PHLF resulted in patient death [79].
While hemodynamic parameters did improve acutely with intraoperative somatostatin therapy,
this last case series highlights the importance of initiating somatostatin therapy prior to completing
hepatectomy, and not after when considerable liver mass is being removed. At our center, when we
are concerned about the risk for PHLF (in general, when we are leaving roughly 30% of pre-operative
mass for normal livers or 40% for livers that are cholestatic, steatotic, or have previously undergone
extensive chemotherapy), somatostatin is started prior to ligating the main portal vein branch feeding
the liver being resected. We give somatostatin as a bolus of 250 µg in patients <65 kg or 500 µg in
patients ≥65 kg, followed by a five-day infusion of 250 µg/h. Among major hepatectomy patients
treated according to this protocol at our center in recent years, there has been no perioperative mortality,
and rates of PHLF grades B (deviation from the regular postoperative clinical pathway managed
without invasive treatment) and C (PHLF requiring an invasive procedure) [5] have been 9% and 2%,
respectively (unpublished data).
Overall, the experimental and clinical evidence available to date suggests that the perioperative
administration of somatostatin or its analogue octreotide following major hepatectomy may suppress
regeneration but, at the same time, help achieve more orderly regeneration and reduced injury and
inflammation during regeneration via a mechanism that may depend, at least in part, on the Met
salvage pathway and the production of 5’-MTA.
4.2. Following Liver Transplantation
Mechanical flow derivations, namely portosystemic shunts, have been used to reduce PVF and
PVP reaching “small-for-size” liver grafts [17,20]. However, these are relatively permanent solutions for
a temporary problem, as the critical period of flow-induced injury is limited [80]. Somatostatin therapy
offers a reversible means for reducing portal flow and pressure in the early post-transplant period,
while the liver graft is still adapting to the altered physiology in the recipient’s body.
Peri-operative somatostatin therapy has been evaluated in animal models of “small-for-size” liver
transplantation. In rat liver transplant recipients, somatostatin given preceding hepatectomy and
following reperfusion of reduced-size grafts produced an acute reduction in post-reperfusion PVP.
During follow-up, somatostatin-treated recipients had lower serum transaminase and bilirubin levels
and reduced intrahepatic expression of ET-1. Heme oxygenase-1 (HO-1) is among the most critical of the
cytoprotective mechanisms activated during cellular stress, exerting antioxidant and anti-inflammatory
functions, modulating the cell cycle, and maintaining microcirculation [81]; expression of HO-1 was
observed to be upregulated in somatostatin-treated grafts. As well, treated grafts had improved hepatic
microstructure, less hepatocellular apoptosis, and significantly better survival at the end of seven days
in comparison with untreated controls (67% vs. 17%, respectively, p = 0.036) [82].
Our group has performed “small-for-size” liver transplantation in the porcine model. Seventy percent
hepatectomy was performed in donor pigs weighing 15–20 kg, and the reduced-size livers were then
transplanted into larger recipients (30–35 kg), avoiding the use of veno-venous bypass by keeping the
anhepatic periods short (<20 min) [83]. Transplanted grafts ultimately represented approximately 20%
of the recipients’ standard liver volumes (Figure 2). With cold ischemic periods of around five hours
and no additional treatment, recipient survival in this model was 26% at five days (5/19 recipients).
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Hepatic hemodynamic parameters measured in the recipients demonstrated acute increases in PVF and
PVP immediately after graft reperfusion, which consequentially produced significant activation and
injury at the level of the hepatic sinusoids. Parameters of hepatic regeneration and proliferative activity
also rose in direct relation to the degree of post-reperfusion portal hyperperfusion [21]. Perioperative
somatostatin therapy, initiated as a bolus during the anhepatic period followed by a continuous five-day
infusion, helped significantly reduce PVF and PVP in this model and achieve slower but more orderly
hepatic regeneration, better recovery of liver function (uptake, synthesis, and excretion, in particular),
and >80% recipient survival at the end of five days [22].Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 7 of 13 
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Figure 2. A 70 partial hepatecto y is performed in a pig weighing 15–20 kg, resulting in a partial
graft weighing approximately 150 g (A). The partial graft is prepared for transplantation (B) and
transplanted into a larger (30–35 kg) recipient, ultimately representing 0.5% of the recipient’s body
weight (C).
In clinical case reports and series, peri-operative somatostatin treatment has been shown to
reduce markers of hepatocellular and SEC injury as well as massive ascites following living donor
liver transplantation [84–86]. As well, in a recent single-center randomized controlled clinical
trial, somatostatin was administered to patients with clinically significant portal hypertension
undergoing liver transplantation with whole liver grafts. Patients in the study were randomized
2:1 to peri-operative somatostatin therapy administered during five days (N = 18) versus placebo
(N = 11). The primary endpoint—≥20% reduction in HVPG in response to somatostatin bolus—was
met in 55% of somatostatin-treated patients and none receiving placebo. Post-reperfusion HVPG was
significantly lower among somatostatin-treated patients, and hepatic artery flows among treated livers
were significantly improved. Though the trial was likely underpowered to do so, no differences in
major measures of clinical outcome (including adverse events, long-term complications, and graft and
patient survival rates) were detected [87].
In liver transplantation, in particular using “small-for-size” grafts, both somatostatin and octreotide
produce immediate improvements in portal hemodynamic parameters that translate into less injury,
slower but more histologically-normal regeneration, and improved hepatic function in the early
post-transplant period.
5. Summary and Future Directions
Figure 3 and Table 1 summarize the effects that have been observed when somatostatin or its
analogues have been administered acutely to “small-for-size” liver remnants and grafts in the context
of experimental and a few small clinical trials.
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a more normal balance between parenchymal and non-parenchymal cells. This appears to translate 
into improved liver function during the post-operative period and, consequentially, improved 
survival. 
The results of animal and preliminary human studies are promising. However, more clinical 
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analogue therapy can prevent and/or reverse pathophysiological processes in “small-for-size” livers 
Figure 3. Potential sites and actions of somatostatin (SST) and its a alogues in the spla chnic territories
and the liver. By binding the endothelium and inhibiting secretion of gut-derived vasodilatory peptides,
somatostatin induces vasoconstriction in mesenteric arteries and portocollateral veins and reduces
portal vein flow (PVF). In the “small-for-size” (SFS) liver, lower PVF results in decreased sinusoidal
endothelial cell (SEC) injury. This translates into reduced expression and translation of endothelin-1
(ET-1) mRNA by SECs. By lowering levels of ET-1 as well as acting directly on hepatic stellate
cells (HSCs), somatostatin helps reduce HSC contraction, thereby helping maintain normal hepatic
sinusoidal diameter, reducing portal vein resistance (PVR), and improving hepatic microcirculatory flow.
Better flow at the microvascular level should lead to less hepatocellular injury and improved function
and survival. At the same time, the combined effects of somatostatin on portal inflow and its inhibition
of hepatotropic factor-mediated hepatocellular proliferation and DNA synthesis in hepatocytes result
in suppression of hepatic regeneration.
Table 1. Effects of peri-operative somatostatin or somatostatin analogue therapy on “small-for-size” livers.
Reduces Improves
• Portal vein flow and pressure
• Generation of ascites
• Hepatocellular, SEC, and HSC injury
• Hepatocellular apoptosis
• Hepatocellular proliferation and restoration of hepatic mass
• Intrahepatic growth of tumor cells
• Preservation of normal hepatic microarchitecture
• Hepatic reticuloendothelial system activity
• Hepatic function (e.g., uptake, synthesis, and excretion)
• Patient survival
While they decrease regeneration of hepatocytes and the rate of restoration of hepatic mass,
somatostatin and its analogues appear to improve the manner in which mass is restored, maintaining a
more normal balance between parenchymal and non-parenchymal cells. This appears to translate into
improved liver function during the post-operative period and, consequentially, improved survival.
The results of animal and preliminary human studies are promising. However, more clinical
work still needs to be done to determine the true extent to which perioperative somatostatin or
analogue therapy can prevent and/or reverse pathophysiological processes in “small-for-size” livers
and the mechanism(s) by which they may do so, including the impact they may have on the bile
acid/FXR/FGF19/FGFR4 and Met salvage pathways. Currently, at least one multicenter randomized
controlled trial is underway to determine whether perioperative somatostatin infusion can decrease
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post-operative ascites following open resection of hepatocellular carcinoma [88], and another trial has
been registered to evaluate whether administration of somatostatin can aid in recovery from PHLF that
has already been established (NCT02882347, https://clinicaltrials.gov/). In the future, if it is determined
that somatostatin or its analogues can safely and consistently help avoid SFSS/PHLF and associated
morbidity and mortality, these agents may find greater application in and help expand the clinical
indication of major liver resection and partial liver transplantation for the treatment of liver tumors
and end-stage liver disease.
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